Latest Strategic Partnerships News

Accelerate Resources has secured a major earn-in agreement for the Balagundi Gold Project near Kalgoorlie and reported promising maiden drilling results at Kanowna East, while strategically divesting its Comet Gold Project stake.

Syrah Resources resumed graphite production at its Balama mine and advanced its Vidalia anode material facility amid supportive US trade tariffs and tax credits, positioning itself strongly in the growing EV battery market.

Gold Hydrogen Limited has closed a $14.5 million strategic investment round led by Toyota, Mitsubishi Gas Chemical, and ENEOS Xplora, positioning the company to accelerate drilling and commercialisation efforts at its Ramsay Project in South Australia.

Alliance Nickel has appointed financial advisors to explore a SPAC transaction for a Nasdaq listing, aiming to tap into premium US capital markets for its NiWest Nickel-Cobalt Project. The move follows a robust feasibility study and a strategic partnership with automaker Stellantis.

Liontown Resources reported a robust September quarter, doubling underground ore output and strengthening its balance sheet to $420 million. The company’s FY26 guidance confirms a strategic shift to underground mining with anticipated cost improvements.

Zeotech Limited has locked in a $204 million binding offtake agreement for its kaolin products and successfully demonstrated its AusPozz™ low-carbon metakaolin in a large-scale concrete pour, signaling strong momentum in its commercialisation efforts.

Breakthrough Minerals reports encouraging soil sampling results at its Errolls Gold Project in Western Australia, setting the stage for imminent reverse circulation drilling. The company maintains a solid cash position of approximately AUD 1.68 million to support exploration activities.

The Calmer Co has reported a robust 26% increase in quarterly sales, driven by strong growth in Australia and the US, alongside a significant 39% reduction in cash used in operations, signaling clear progress toward profitability.

The Calmer Co. International Limited has delivered its strongest quarter yet, with revenue surging 26% to $2.4 million and operating cash outflows dropping to a historic low. Strategic growth across retail, e-commerce, and B2B channels underpins its confident path to breakeven.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.

NOVONIX has reached mutual agreement to draw down an additional US$40 million tranche of convertible debentures from Yorkville Advisors, advancing its funding strategy to support growth in battery technology.